Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 4/20 | 0.35 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA9 | Q16790 | 4/20 | 0.35 |
| ▸ | CA7 | P43166 | 3/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28493735 | 0.77 | TSHR (0.37) | TSHRADRA1APDE4DCA12CA1 | |
| SCHEMBL297916 | 0.76 | TSHR (0.59) | TSHRADRA1APDE4DCA12CA1 | |
| SCHEMBL5146416 | 0.74 | — | — | |
| SCHEMBL27926059 | 0.74 | TSHR (0.56) | TSHRADRA1APDE4DCA12CA1 | |
| SCHEMBL5070177 | 0.72 | — | — | |
| SCHEMBL5886602 | 0.72 | TSHR (0.37) | TSHRADRA1APDE4DCA12CA1 | |
| SCHEMBL28503411 | 0.72 | TSHR (0.37) | TSHRADRA1APDE4DCA12CA1 | |
| SCHEMBL11510451 | 0.71 | TSHR (0.53) | TSHRADRA1APDE4DCA12CA1 | |
| SCHEMBL20565358 | 0.71 | TSHR (0.53) | TSHRADRA1APDE4DCA12CA1 | |
| SCHEMBL3387637 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150491-B2 | Bicyclohexane derivative compound and manufacturing method of the same | MITSUBISHI GAS CHEMICAL COMPANY, INC (JP) | 2015-10-06 | — | — | US | disclosed |
| US-8598292-B2 | Adamantane derivative, method for producing same, polymer using same as starting material, and resin composition | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2013-12-03 | — | — | US | disclosed |
| US-20130030211-A1 | BICYCLOHEXANE DERIVATIVE COMPOUND AND MANUFACTURING METHOD OF THE SAME | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2013-01-31 | — | — | US | disclosed |
| EP-2524907-A1 | BICYCLOHEXANE DERIVATIVE AND PRODUCTION METHOD FOR SAME | Mitsubishi Gas Chemical Company, Inc. (JP) | 2012-11-21 | — | — | EP | disclosed |
| US-20110319584-A1 | ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING SAME, POLYMER USING SAME AS STARTING MATERIAL, AND RESIN COMPOSITION | MITSUBISHI GAS CHEMICAL COMPANY, INC (JP) | 2011-12-29 | — | — | US | disclosed |
| US-7078562-B2 | Adamantane derivatives and resin compositions using the same as raw material | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2006-07-18 | — | — | US | disclosed |
| US-7067692-B2 | Production method of adamantyl acrylate compounds | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2006-06-27 | — | — | US | disclosed |
| US-20050158662-A1 | Adamantane derivatives and resin compositions using the same as raw material | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2005-07-21 | — | — | US | disclosed |
| US-20040210082-A1 | Production method of adamantyl acrylate compounds | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2004-10-21 | — | — | US | disclosed |
| EP-1468981-A1 | Production method of adamantyl acrylate compounds | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2004-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040210082-A1 | Production method of adamantyl acrylate compounds | APEH, CYP51A1, NAAA | TSHR 1613/4885ADRA1A 725/4885PDE4D 855/4885 |
| US-20130030211-A1 | BICYCLOHEXANE DERIVATIVE COMPOUND AND MANUFACTURING METHOD OF THE SAME | DDT, CYP1A2, CYP1B1 | TSHR 1375/4885ADRA1A 1139/4885PDE4D 1987/4885 |
| US-20110319584-A1 | ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING SAME, POLYMER USING SAME AS STARTING MATERIAL, AND RESIN COMPOSITION | EEF1A1, ADGRF1, ERCC4 | TSHR 3042/4885ADRA1A 236/4885PDE4D 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.